Overview


According to FutureWise analysis the market for Syphilis Immunoassay Diagnostics in 2023 is US$ 0.33 billion, and is expected to reach US$ 0.45 billion by 2031 at a CAGR of 3.70%.

Syphilis is a bacterial chronic disease that mostly spreads through sexual activity. It can be treated with antibiotics, particularly in the beginning stages. One of the worst STIs, it is brought on by the Treponema pallidum bacteria and, if untreated, can have long-term effects. The main procedures for diagnosing the illness are clinical observations and serologic tests. For the serologic diagnosis of syphilis, the distinction between treponemal and nontreponemal antibodies must be made. In many places, the syphilis testing prototype has been repurposed to diagnose with a treponemal antibody test, pointing to a nontreponemal test if the treponemal antibody test is found positive. Many methods, such as the RPR test, the enzyme immunoassay (EIA test), the venereal disease research laboratory (VDRL test), and a few others, are used to diagnose cases of syphilis. The diagnosis of syphilis always requires a high level of clinical suspicion and routine screening for those at higher risk. The increased prevalence of syphilis, which mostly affects gay and bisexual people, is considered as a global health concern. As a result, the government is making efforts to increase awareness of Syphilis Immunoassay Diagnostics, which will subsequently fuel the market's growth in the near future.

A serious bacterial infection that affects both men and women is known as syphilis. It is also seen in individuals with HIV. Syphilis must always be diagnosed with high clinical suspicion and regularly checked populations. The conventional screening strategy for syphilis has recently been reversed due to the availability of quick, automated treponemal diagnostics. Blood tests can be used to identify syphilis. Blood tests can verify antibodies that the body develops to fight the infection. The test can establish whether an infection is present or past because the antibodies to combat the syphilis-causing bacteria stay in the body for years. The growth of the global market for syphilis immunoassay diagnostics can be attributed to an increase in the incidence of syphilis infections worldwide brought on by unprotected sex between men and men and men and women.

Rising prevalence of syphilis especially among gay and bisexual men and women, is now seen as a global health threat. The danger of mother-to-child transmission during pregnancy, which can have disastrous pregnancy outcomes, makes syphilis in women of childbearing age particularly worrisome. In addition, every new incidence of syphilis is a dangerous infection with a risk of complications including neurosyphilis or increased HIV transmission. The government is therefore starting campaigns to increase awareness about Syphilis Immunoassay Diagnostics, which will fuel market expansion during the forecast period, in order to protect the populace from such infections. Worldwide, immunoassay-based diagnoses are becoming more and more common. Disease control relies heavily on public awareness initiatives designed to help people recognise the signs and symptoms of infectious diseases and learn how to avoid them. Immunoassays are very popular since patients are more aware of them. For instance, the advocacy programme of the International Society for Infectious Diseases focuses on working with clinicians, public health practitioners, and researchers all over the world to support the sharing of scientific knowledge and the use of evidence-based medicine and public health practises. The outcomes of biological study take a very long time to be achieved because the procedure is slow. Any biological invention needs to go through multiple testing stages because various people may react differently to it. Any vaccine must receive the CDC and FDA's approval. As a result, the process for new vaccine development becomes quite difficult. The market for syphilis immunoassay diagnostics is constrained by delays in the approval procedure for new improvements in diagnostics.

FutureWise Market Research has published a report that provides an insightful analysis of syphilis immunoassay diagnostics market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, the syphilis immunoassay diagnostics market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • F. Hoffmann-La Roche AG
  • Bio-Rad Laboratories, Inc.
  • Becton Dickinson (BD)
  • Siemens Healthineers AG
  • DiaSorin S.p.A.
  • Abbott Laboratories
  • Ortho Clinical Diagnostics
  • Shenzhen New Industries Biomedical Engineering Co., Ltd.
  • BioMérieux SA
  • Fujirebio (Miraca Group)

By Product

  • Analyzers
  • Kits & Reagents      

By Technology  

  • Enzyme-linked immunosorbent assay (ELISA)
  • Chemiluminescence Immunoassay (CLIA)
  • Others

By End-User

  • Hospitals
  • Diagnostics Labs
  • Blood Banks
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Regional domination is a result of a number of circumstances, including a high prevalence of syphilis, rising healthcare costs, quick technology development, proactive government measures, and improved consumer knowledge of the disease and its diagnostic tests. Additionally, it is anticipated that a major element enhancing the regional revenue share will be the region's strong presence of the top market players. Market expansion is anticipated to be further fuelled by the rising number of multiplex PCR tests being introduced for the diagnosis of sexually transmitted diseases (STDs), such as syphilis. The main driving force is also anticipated to be the growing number of government initiatives, such as the Antimicrobial Stewardship Initiative, that aims to hasten the development and adoption of quick diagnostic techniques. Also, high awareness among Americans is the primary cause of the rising number of tests and screening processes for the detection of syphilis. It is anticipated that expanding strategic initiatives will promote market expansion along with the increasing commercialization of diagnostic products.


  • Tier 1 players- established companies in the market with major market share
  • Tier 2 players
  • New Entrants
  • Emerging players which are growing rapidly

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data points affecting market growth

  • To provide with an exhaustive analysis on the Syphilis Immunoassay Diagnostics Market by product, by technology, by end-user and by region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches.

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

 

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Syphilis Immunoassay Diagnostics Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Syphilis Immunoassay Diagnostics Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Syphilis Immunoassay Diagnostics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Syphilis Immunoassay Diagnostics Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Analyzers
        2. Kits & Reagents

  • 8.   Syphilis Immunoassay Diagnostics Market, By Technology Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Enzyme-linked immunosorbent assay (ELISA)
        2. Chemiluminescence Immunoassay (CLIA)
        3. Others

  • 9.   Syphilis Immunoassay Diagnostics Market, By End-User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Diagnostics Labs
        3. Blood Banks
        4. Others

  • 10.   North America Syphilis Immunoassay Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Syphilis Immunoassay Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Syphilis Immunoassay Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Syphilis Immunoassay Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. F. Hoffmann-La Roche AG
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Bio-Rad Laboratories, Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Becton Dickinson (BD)
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Siemens Healthineers AG
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. DiaSorin S.p.A.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Abbott Laboratories
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Ortho Clinical Diagnostics
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Shenzhen New Industries Biomedical Engineering Co., Ltd.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. BioMérieux SA
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10.Fujirebio (Miraca Group)
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients